How much do PCSK9 inhibitors lower LDL?

Added to a statin, they lower LDL cholesterol by about 50 to 60%, often bringing it below 40 mg/dL. They lower apoB in step, and they also lower lipoprotein(a) by roughly a quarter. No other drug class lowers LDL this much.

Are PCSK9 inhibitors safe?

Yes, they are among the better-tolerated cholesterol drugs. The most common side effect is a mild injection-site reaction, and they do not cause the muscle symptoms some people get from statins. Concerns that very low LDL might harm the brain were tested in a dedicated cognitive study and not borne out. The main practical downsides are the injections, the cost, and insurance approval.

Do PCSK9 inhibitors reduce heart attacks?

Yes, in high-risk people. In large trials, adding a PCSK9 inhibitor to a statin lowered heart attacks and strokes by about 15% in people with established heart disease, and a 2025 trial showed benefit in high-risk people who had not yet had an event. The proven benefit is in nonfatal heart attacks and strokes; a clear reduction in deaths has been harder to demonstrate.

How much do PCSK9 inhibitors lower LDL?

Added to a statin, they lower LDL cholesterol by about 50 to 60%, often bringing it below 40 mg/dL. They lower apoB in step, and they also lower lipoprotein(a) by roughly a quarter. No other drug class lowers LDL this much.

Are PCSK9 inhibitors safe?

Yes, they are among the better-tolerated cholesterol drugs. The most common side effect is a mild injection-site reaction, and they do not cause the muscle symptoms some people get from statins. Concerns that very low LDL might harm the brain were tested in a dedicated cognitive study and not borne out. The main practical downsides are the injections, the cost, and insurance approval.

Do PCSK9 inhibitors reduce heart attacks?

Yes, in high-risk people. In large trials, adding a PCSK9 inhibitor to a statin lowered heart attacks and strokes by about 15% in people with established heart disease, and a 2025 trial showed benefit in high-risk people who had not yet had an event. The proven benefit is in nonfatal heart attacks and strokes; a clear reduction in deaths has been harder to demonstrate.

PCSK9 Inhibitors (Repatha, Praluent): The Strongest LDL Drugs | Philadelphia

TL;DR30-second take

PCSK9 inhibitors are injectable antibodies, evolocumab (Repatha) and alirocumab (Praluent), that lower LDL cholesterol by about 50 to 60% on top of a statin, more than any other drug class. They block PCSK9, a protein that destroys the liver's LDL receptors, so the liver clears more cholesterol. In large trials of people with heart disease they lowered heart attacks and strokes by about 15%, and a 2025 trial extended that benefit to high-risk people who had not yet had a heart attack. They are self-injected every 2 to 4 weeks and well tolerated, but expensive and usually reserved for when a statin plus ezetimibe is not enough.

TL;DR: PCSK9 inhibitors are injectable antibodies, evolocumab (Repatha) and alirocumab (Praluent), that lower LDL cholesterol by about 50 to 60% on top of a statin, more than any other drug class. They work by blocking PCSK9, a protein that destroys the liver's LDL receptors, so the liver clears more cholesterol from the blood. In large trials of people who already had heart disease, they lowered heart attacks and strokes by about 15%, and a 2025 trial extended that benefit to high-risk people who had not yet had a heart attack. They are self-injected every 2 to 4 weeks, tolerated well, and safe even when they drive LDL very low, but they are expensive and usually reserved for people whose LDL or apoB stays high on a statin plus ezetimibe. One caveat: the first big trial showed fewer heart attacks and strokes but no drop in deaths, so the benefit is about preventing nonfatal events.

What are PCSK9 inhibitors, and how do they work?

PCSK9 inhibitors are a class of cholesterol drugs built around one discovery: a protein called PCSK9 that controls how well your liver clears LDL. Your liver pulls LDL out of the blood using LDL receptors on its surface. PCSK9 latches onto those receptors and marks them for destruction, so the more PCSK9 you have, the fewer receptors survive and the higher your LDL climbs. Block PCSK9, and the receptors last longer, clearing more LDL.

Evolocumab (Repatha) and alirocumab (Praluent) are monoclonal antibodies, lab-made proteins that bind and neutralize the PCSK9 floating in your blood. With PCSK9 mopped up, LDL receptors survive and recycle, and LDL falls. This is the same target as inclisiran, the twice-yearly injection, but reached by a different route: the antibodies remove the PCSK9 protein directly, while inclisiran tells the liver to make less of it in the first place.

How much do they lower cholesterol?

The reduction is large. Added on top of a statin, PCSK9 antibodies lower LDL cholesterol by roughly 50 to 60%, which can bring an LDL of 100 mg/dL down to the low 40s. That makes them the most powerful LDL-lowering drugs available. They lower apoB, the particle count that tracks arterial risk most closely, in step with LDL. As a bonus, they also lower lipoprotein(a), or Lp(a), by about a quarter, a modest drop on a risk marker that few other drugs touch.

The size of the drop is why these drugs matter for people who need aggressive lowering: someone with an inherited cholesterol disorder, or a person at very high risk whose LDL stays stubbornly high on a statin and ezetimibe.

Do PCSK9 inhibitors prevent heart attacks?

Yes, and this is well proven for people who already have heart disease. In the FOURIER trial of more than 27,000 people with established heart disease already on a statin, evolocumab lowered LDL by about 59%, to a median around 30 mg/dL, and reduced the combined rate of heart attacks, strokes, and related events by about 15%.¹ A second trial, ODYSSEY OUTCOMES, tested alirocumab in nearly 19,000 people after a recent heart attack or unstable angina and found a similar 15% reduction in cardiovascular events.²

The details matter. In FOURIER, the benefit came from fewer nonfatal heart attacks and strokes; the trial did not show a reduction in cardiovascular death or death from any cause. ODYSSEY OUTCOMES hinted at a reduction in overall death, but that finding was a secondary signal rather than firm proof, because of how the trial's statistics were structured. So the grounded claim is that these drugs reliably reduce nonfatal heart attacks and strokes in high-risk people, and may help with survival, without that survival benefit being nailed down.

Are they safe, even when LDL goes very low?

They are among the better-tolerated cholesterol drugs. The most common issue is a mild reaction at the injection site. Because they work in the bloodstream on a single protein rather than inside muscle cells, they do not cause the muscle aches that lead some people to stop statins.

The natural worry is whether driving LDL as low as these drugs do, sometimes under 30 or even 20 mg/dL, causes harm, and a specific concern was the brain, since the brain uses cholesterol. That question was tested directly. In a substudy called EBBINGHAUS, people on evolocumab underwent detailed cognitive testing, and their scores were no worse than those on placebo.³ Very low LDL has looked safe across the trial years so far, which is reassuring, though the longest careful follow-up runs to several years rather than decades.

The 2025 update: benefit before a first heart attack

For years, the proof for PCSK9 inhibitors came from people who already had heart disease. That changed in 2025. The VESALIUS-CV trial tested evolocumab in more than 12,000 people at high cardiovascular risk who had not yet had a heart attack or stroke, and it met its goals: evolocumab lowered the risk of major cardiovascular events by about 25%, and by about 19% on a broader measure that included artery procedures.⁴ The benefit reached even a subgroup with diabetes and no known artery disease.

This extends the drug's proven reach from secondary prevention, treating people who have already had an event, into high-risk primary prevention, heading off a first event in people whose risk is high. Two cautions keep it grounded: most people in the trial still had some underlying artery disease, so this is high-risk rather than average-risk prevention, and the hints of a survival benefit there, as in the earlier trials, remain preliminary. Still, it is a meaningful widening of who these drugs can help.

Who are PCSK9 inhibitors for, and what do they cost?

Guidelines place them after the basics. The standard path is a statin at the highest tolerated dose, then ezetimibe, and then a PCSK9 inhibitor if LDL or apoB is still above target, most often in people with established heart disease or an inherited cholesterol disorder. They are the heavy artillery, brought in when large lowering is needed and the oral drugs have not gotten there.

They are self-injected under the skin. Evolocumab is given as one shot every 2 weeks or a larger monthly shot; alirocumab is given every 2 weeks, with a monthly option. The main barriers are cost and paperwork. At launch in 2015 they ran about $14,000 a year, which limited use; the makers cut the price about 60%, to roughly $5,850 a year, in 2018, and they remain subject to insurance prior authorization. For the right high-risk patient, though, the combination of large, proven LDL lowering and good tolerability makes them one of the most valuable tools in prevention.

Guidance from the Clinic

"PCSK9 inhibitors are the closest thing we have to a precision cholesterol tool. When someone has an inherited cholesterol disorder, or has had a heart attack and their LDL will not come down far enough on a statin and ezetimibe, these drugs cut the number in half again and, in the trials, cut the heart attacks and strokes that follow. I am careful about two things. First, I set the expectation clearly: in the first big trial they lowered events but did not lower deaths, so I frame them as powerful protection against nonfatal heart attacks and strokes. Second, I do the work on access, because the price and the prior authorization are the true obstacles for most people rather than the medicine. The 2025 data extending the benefit to people who have not yet had an event is exciting, and it is going to change who I offer this to."

Key Takeaways

PCSK9 inhibitors, evolocumab (Repatha) and alirocumab (Praluent), are injectable antibodies that lower LDL cholesterol by about 50 to 60% on top of a statin, the largest drop of any drug class.
They work by blocking PCSK9, a protein that destroys the liver's LDL receptors, and they lower apoB in step and lipoprotein(a) by about a quarter.
In people with established heart disease, they lowered heart attacks and strokes by about 15%; the proven benefit is in nonfatal events rather than a clear reduction in deaths.
The 2025 VESALIUS-CV trial extended the benefit to high-risk people who had not yet had a heart attack or stroke.
They are self-injected every 2 to 4 weeks, tolerated well and safe even at very low LDL over trial years, but expensive and usually reserved for when a statin plus ezetimibe is not enough.

Beyond Statins: Lowering Cholesterol - where PCSK9 inhibitors fit among the options
Inclisiran (Leqvio) - the twice-yearly injection that targets the same protein
Ezetimibe (Zetia) - the oral add-on that comes before a PCSK9 inhibitor
ApoB and Heart Health - the particle count these drugs lower
What Is a Preventive Cardiologist? - how these choices get made

Scientific References

Sabatine MS, Giugliano RP, Keech AC, et al. "Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease." New England Journal of Medicine. 2017;376(18):1713-1722.
Schwartz GG, Steg PG, Szarek M, et al. "Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome." New England Journal of Medicine. 2018;379(22):2097-2107.
Giugliano RP, Mach F, Zavitz K, et al. "Cognitive Function in a Randomized Trial of Evolocumab." New England Journal of Medicine. 2017;377(7):633-643.
Bohula EA, Marston NA, Sabatine MS, et al. "Evolocumab in Patients without a Previous Myocardial Infarction or Stroke." New England Journal of Medicine. 2026;394(2):117-127.

Fishtown Medicine | Cardiovascular risk

2418 E York St, Philadelphia, PA 19125(267) 360-7927 hello@fishtownmedicine.comHSA/FSA Eligible

Start your intake

Frequently Asked Questions

Common Questions

Both lower LDL by targeting the same protein, PCSK9, but by different means. Evolocumab and alirocumab are antibodies that remove PCSK9 from the blood and are self-injected every 2 to 4 weeks. Inclisiran is a small RNA that tells the liver to make less PCSK9 and is given by a clinician twice a year. The antibodies have large trials proving they lower heart attacks and strokes; inclisiran has proof that it lowers LDL, with its outcome trials still to report.

Deep-Dive Questions

The liver clears LDL from the blood using LDL receptors, and the number of working receptors sets how fast LDL comes down. PCSK9 is the protein that limits that number: it binds a receptor after it has pulled in an LDL particle and sends it to be destroyed rather than recycled back to the surface. Removing PCSK9 lets each receptor be reused many times, so the liver clears much more LDL with the same machinery. Because this lever is so central, blocking it lowers LDL by 50 to 60% even on top of a statin, which is already boosting receptor numbers by a different mechanism. That is two levers on the same system, working together.

FOURIER followed people for a median of about 2 years, which is a short window in which to change the death rate, and the trial enrolled people whose heart disease was already treated with statins, so their baseline risk of dying in that window was lower than it once would have been. The drug reduced nonfatal heart attacks and strokes, the events that accumulate first, but the follow-up was probably too short, and the population too well-treated, to show a survival difference. Whether a longer or larger trial would reveal one is still an open question, and the absolute benefit, while genuine, was modest: the event rate fell from about 11 to about 10% over the trial.

Usually the answer starts with cheaper, proven steps. For a person without heart disease, the first moves are lifestyle, a statin, and ezetimibe, which handle most cases and are inexpensive. PCSK9 inhibitors enter the picture when LDL or apoB stays high despite those, particularly with a strong family history or an inherited cholesterol disorder, or when the overall risk is high. The 2025 VESALIUS-CV trial widened that door for high-risk people without prior events, but the evidence still centers on high-risk populations rather than average-risk adults with mildly high numbers. The decision belongs in the context of your whole risk picture, which is the preventive cardiology approach.

This worries people, because cholesterol is essential for cells and the brain. So far, the trials are reassuring. People who reached very low LDL, under 20 or 30 mg/dL, on these drugs did not show more harm than those with higher levels over the trial years, and the dedicated brain-function study found no cognitive downside. The body also makes its own cholesterol where it needs it, independent of blood LDL. The one limit is time: the careful follow-up runs several years rather than a lifetime, so while there is no signal of harm, decades-long safety is still being gathered.

Ready when you are